BPMC250117C140000
- 0.40
- -0.40-50.00%
Blueprint Medicines Newsroom
J.P. Morgan's Top Healthcare Stocks for 2025
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Guggenheim Reiterates Buy on Blueprint Medicinesto Buy
Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
Blueprint Medicines: A Promising Investment With Innovative Treatments and Strong Financial Position
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Breakeven On The Horizon For Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing
Express News | Blueprint Medicines Corp : Raymond James Raises Target Price to $130 From $125
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
H.C. Wainwright Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
J.P. Morgan Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $126
Express News | Blueprint Medicines Corp : JP Morgan Initiates Coverage With Overweight Rating; Target Price $126
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105